jurkat  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    ATCC jurkat
    SF3B1 is posttranslationally regulated in T cell leukemia. ( A ) Relative essentiality of the U2 splicing complex components across different types of cancers. Essentiality data were obtained from the Project Achilles CRISPR-Cas9 screening dataset for 563 cancer cell lines. ( B ) Immunoblot showing SF3B1 protein level in patients versus T cells [see fig. S2D for the quantification of protein levels, (N1-IC, NOTCH1 intracellular domain)]. ( C ) Reverse transcription reaction coupled to reverse transcription polymerase chain reaction (RT-PCR) for the SF3B1 mRNA expression <t>in</t> <t>T-ALL</t> versus T cells in human sample ( n = 3). * P ≤ 0.05. ( D ) RPPA analysis for SF3B1 protein levels in HR ( n = 17) versus non-HR ( n = 25) patient cases. ( E ) Immunoblot indicating SF3B1 protein expression level in CUTLL1 and <t>JURKAT</t> cells treated with 10 μM PR619, 2 μM b-AP15, or 200 nM ML323 (24 hours). GAPDH is used as the loading control. ( F ) SF3B1 protein level upon treatment of CUTLL1 and JURKAT with 10 μM P5091 for 24 hours. ( G ) Representative coimmunoprecipitation analysis of USP7 (left) and SF3B1 (right) to evaluate the interaction between USP7 and SF3B1 in CUTLL1 cells. IP, immunoprecipitation; IgG, immunoglobulin G. ( H ) Representative immunoblot of SF3B1 protein expression upon treatment with cycloheximide (CHX) (10 μg/ml) in control - and shUSP7 -expressing RPMI-8402 cells for 12 hours. Quantification of protein levels is shown (right). ( I ) Representative immunoblot of SF3B1 protein expression upon treatment of cells with 10 μM P5091 (24 hours). ( J ) Immunoprecipitation of Flag-tagged SF3B1 coupled to immunoblot analysis for detection of SF3B1 ubiquitination in 293T cells cotransfected with hemagglutinin (HA)–tagged or HA-K63O (only K63 can be ubiquitinated) ubiquitin (Ub) construct and Flag-SF3B1.
    Jurkat, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/jurkat/product/ATCC
    Average 96 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    jurkat - by Bioz Stars, 2022-10
    96/100 stars

    Images

    1) Product Images from "SF3B1 homeostasis is critical for survival and therapeutic response in T cell leukemia"

    Article Title: SF3B1 homeostasis is critical for survival and therapeutic response in T cell leukemia

    Journal: Science Advances

    doi: 10.1126/sciadv.abj8357

    SF3B1 is posttranslationally regulated in T cell leukemia. ( A ) Relative essentiality of the U2 splicing complex components across different types of cancers. Essentiality data were obtained from the Project Achilles CRISPR-Cas9 screening dataset for 563 cancer cell lines. ( B ) Immunoblot showing SF3B1 protein level in patients versus T cells [see fig. S2D for the quantification of protein levels, (N1-IC, NOTCH1 intracellular domain)]. ( C ) Reverse transcription reaction coupled to reverse transcription polymerase chain reaction (RT-PCR) for the SF3B1 mRNA expression in T-ALL versus T cells in human sample ( n = 3). * P ≤ 0.05. ( D ) RPPA analysis for SF3B1 protein levels in HR ( n = 17) versus non-HR ( n = 25) patient cases. ( E ) Immunoblot indicating SF3B1 protein expression level in CUTLL1 and JURKAT cells treated with 10 μM PR619, 2 μM b-AP15, or 200 nM ML323 (24 hours). GAPDH is used as the loading control. ( F ) SF3B1 protein level upon treatment of CUTLL1 and JURKAT with 10 μM P5091 for 24 hours. ( G ) Representative coimmunoprecipitation analysis of USP7 (left) and SF3B1 (right) to evaluate the interaction between USP7 and SF3B1 in CUTLL1 cells. IP, immunoprecipitation; IgG, immunoglobulin G. ( H ) Representative immunoblot of SF3B1 protein expression upon treatment with cycloheximide (CHX) (10 μg/ml) in control - and shUSP7 -expressing RPMI-8402 cells for 12 hours. Quantification of protein levels is shown (right). ( I ) Representative immunoblot of SF3B1 protein expression upon treatment of cells with 10 μM P5091 (24 hours). ( J ) Immunoprecipitation of Flag-tagged SF3B1 coupled to immunoblot analysis for detection of SF3B1 ubiquitination in 293T cells cotransfected with hemagglutinin (HA)–tagged or HA-K63O (only K63 can be ubiquitinated) ubiquitin (Ub) construct and Flag-SF3B1.
    Figure Legend Snippet: SF3B1 is posttranslationally regulated in T cell leukemia. ( A ) Relative essentiality of the U2 splicing complex components across different types of cancers. Essentiality data were obtained from the Project Achilles CRISPR-Cas9 screening dataset for 563 cancer cell lines. ( B ) Immunoblot showing SF3B1 protein level in patients versus T cells [see fig. S2D for the quantification of protein levels, (N1-IC, NOTCH1 intracellular domain)]. ( C ) Reverse transcription reaction coupled to reverse transcription polymerase chain reaction (RT-PCR) for the SF3B1 mRNA expression in T-ALL versus T cells in human sample ( n = 3). * P ≤ 0.05. ( D ) RPPA analysis for SF3B1 protein levels in HR ( n = 17) versus non-HR ( n = 25) patient cases. ( E ) Immunoblot indicating SF3B1 protein expression level in CUTLL1 and JURKAT cells treated with 10 μM PR619, 2 μM b-AP15, or 200 nM ML323 (24 hours). GAPDH is used as the loading control. ( F ) SF3B1 protein level upon treatment of CUTLL1 and JURKAT with 10 μM P5091 for 24 hours. ( G ) Representative coimmunoprecipitation analysis of USP7 (left) and SF3B1 (right) to evaluate the interaction between USP7 and SF3B1 in CUTLL1 cells. IP, immunoprecipitation; IgG, immunoglobulin G. ( H ) Representative immunoblot of SF3B1 protein expression upon treatment with cycloheximide (CHX) (10 μg/ml) in control - and shUSP7 -expressing RPMI-8402 cells for 12 hours. Quantification of protein levels is shown (right). ( I ) Representative immunoblot of SF3B1 protein expression upon treatment of cells with 10 μM P5091 (24 hours). ( J ) Immunoprecipitation of Flag-tagged SF3B1 coupled to immunoblot analysis for detection of SF3B1 ubiquitination in 293T cells cotransfected with hemagglutinin (HA)–tagged or HA-K63O (only K63 can be ubiquitinated) ubiquitin (Ub) construct and Flag-SF3B1.

    Techniques Used: CRISPR, Reverse Transcription Polymerase Chain Reaction, Expressing, Immunoprecipitation, Construct

    SF3B1 silencing or inhibition blocks growth of T cell leukemia. ( A ) Immunoblot indicating SF3B1 depletion in CUTLL1 and JURKAT cells. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. ( B ) CUTLL1 and JURKAT cells were counted at the indicated time points, and cell growth was plotted as shown for the shSF3B1#1 - and shSF3B1#2 -expressing cell populations ( n = 3). ( C ) Luciferase-expressing CUTLL1 cells were transduced with control or shSF3B1#2 and injected intravenously (retro-orbitally) into immunocompromised mice. Luminescence analysis for representative mice on days 8 and 24 (left) and luminescence intensity fold change between days 8 and 24 are shown (right: control , n = 5; shSF3B1#2 , n = 6). ( D ) Survival curve analysis of mice from (C). * P ≤ 0.05 and ** P ≤ 0.01. ( E ) E7107 treatment schema in the xenograft model. ( F ) Luciferase-expressing CUTLL1 cells were intravenously (tail vein) injected into immunocompromised mice followed by 8 days of E7107 administration (at 5 mg/kg per day) starting on the 10th day after transplantation. Luminescence images for representative mice on days 10 and 20 (left) and luminescence intensity fold change between days 10 and 20 are shown (right: vehicle, n = 9; E7107, n = 9). ( G ) Survival analysis of mice from (F). ( H ) Mouse spleen size (left) and weight (right) upon E7107 treatment of the NOTCH1-δE-Cherry + retroviral T-ALL model [vehicle ( n = 3), E7107 ( n = 5)]. ( I ) Representative mice body weight, liver weight, and spleen weight analysis upon treatment with E7107. ( J ) Representative hematoxylin and eosin (H E) staining of esophagus, stomach, jejunum, and ileum (×200 magnification).
    Figure Legend Snippet: SF3B1 silencing or inhibition blocks growth of T cell leukemia. ( A ) Immunoblot indicating SF3B1 depletion in CUTLL1 and JURKAT cells. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. ( B ) CUTLL1 and JURKAT cells were counted at the indicated time points, and cell growth was plotted as shown for the shSF3B1#1 - and shSF3B1#2 -expressing cell populations ( n = 3). ( C ) Luciferase-expressing CUTLL1 cells were transduced with control or shSF3B1#2 and injected intravenously (retro-orbitally) into immunocompromised mice. Luminescence analysis for representative mice on days 8 and 24 (left) and luminescence intensity fold change between days 8 and 24 are shown (right: control , n = 5; shSF3B1#2 , n = 6). ( D ) Survival curve analysis of mice from (C). * P ≤ 0.05 and ** P ≤ 0.01. ( E ) E7107 treatment schema in the xenograft model. ( F ) Luciferase-expressing CUTLL1 cells were intravenously (tail vein) injected into immunocompromised mice followed by 8 days of E7107 administration (at 5 mg/kg per day) starting on the 10th day after transplantation. Luminescence images for representative mice on days 10 and 20 (left) and luminescence intensity fold change between days 10 and 20 are shown (right: vehicle, n = 9; E7107, n = 9). ( G ) Survival analysis of mice from (F). ( H ) Mouse spleen size (left) and weight (right) upon E7107 treatment of the NOTCH1-δE-Cherry + retroviral T-ALL model [vehicle ( n = 3), E7107 ( n = 5)]. ( I ) Representative mice body weight, liver weight, and spleen weight analysis upon treatment with E7107. ( J ) Representative hematoxylin and eosin (H E) staining of esophagus, stomach, jejunum, and ileum (×200 magnification).

    Techniques Used: Inhibition, Expressing, Luciferase, Transduction, Injection, Mouse Assay, Transplantation Assay, Staining

    SF3B1 activity is critical for CHEK2 levels and DNA damage response. ( A ) γH2AX level in CUTLL1 and JURKAT cells treated with 3 nM E7107 for 24 hours. ( B and C ) Representative comet assay photos from CUTLL1 cells treated with 3 nM E7107 for 24 or 48 hours [quantification of (C) in the right panel, n = 45]. ** P ≤ 0.01. ( D ) Metagene analysis of MapR signal around the transcriptional start site in 3 nM E7107 treatment for 24 hours in CUTLL1. DMSO, dimethyl sulfoxide. ( E ) Metagene analysis of normalized transient transcriptome sequencing (TT-seq) reads for protein-coding transcripts (±3-kb area, 3 nM E7107, 15 min). ( F ) Scatterplot of splicing changes in E7107 versus vehicle (FDR
    Figure Legend Snippet: SF3B1 activity is critical for CHEK2 levels and DNA damage response. ( A ) γH2AX level in CUTLL1 and JURKAT cells treated with 3 nM E7107 for 24 hours. ( B and C ) Representative comet assay photos from CUTLL1 cells treated with 3 nM E7107 for 24 or 48 hours [quantification of (C) in the right panel, n = 45]. ** P ≤ 0.01. ( D ) Metagene analysis of MapR signal around the transcriptional start site in 3 nM E7107 treatment for 24 hours in CUTLL1. DMSO, dimethyl sulfoxide. ( E ) Metagene analysis of normalized transient transcriptome sequencing (TT-seq) reads for protein-coding transcripts (±3-kb area, 3 nM E7107, 15 min). ( F ) Scatterplot of splicing changes in E7107 versus vehicle (FDR

    Techniques Used: Activity Assay, Single Cell Gel Electrophoresis, Sequencing

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96
    ATCC ccrf cem ccrf cem
    Fluorescence confocal images of <t>CCRF-CEM</t> cells incubated with FITC-labeled aptamer sgc8 and PE-labeled anti-PTK7. FITC-labeled unselected Library (Lib-FITC) and PE-labeled IgG, which do not bind to CCRF-CEM cells, were used as control. Column 1 is the FITC channel, column 2 is the PE channel, and column 3 is the overlay of the two channels. Cells in row 1 were incubated with Lib-FITC (control) and IgG-PE (control). Cells in row 2 were incubated with Lib-FITC (control) and anti-PTK7-PE. Cells in row 3 were incubated with sgc8-FITC and anti-PTK7-PE.
    Ccrf Cem Ccrf Cem, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ccrf cem ccrf cem/product/ATCC
    Average 96 stars, based on 2 article reviews
    Price from $9.99 to $1999.99
    ccrf cem ccrf cem - by Bioz Stars, 2022-10
    96/100 stars
      Buy from Supplier

    Image Search Results


    Fluorescence confocal images of CCRF-CEM cells incubated with FITC-labeled aptamer sgc8 and PE-labeled anti-PTK7. FITC-labeled unselected Library (Lib-FITC) and PE-labeled IgG, which do not bind to CCRF-CEM cells, were used as control. Column 1 is the FITC channel, column 2 is the PE channel, and column 3 is the overlay of the two channels. Cells in row 1 were incubated with Lib-FITC (control) and IgG-PE (control). Cells in row 2 were incubated with Lib-FITC (control) and anti-PTK7-PE. Cells in row 3 were incubated with sgc8-FITC and anti-PTK7-PE.

    Journal: Journal of proteome research

    Article Title: Cell-Specific Aptamer Probes for Membrane Protein Elucidation in Cancer Cells

    doi: 10.1021/pr700894d

    Figure Lengend Snippet: Fluorescence confocal images of CCRF-CEM cells incubated with FITC-labeled aptamer sgc8 and PE-labeled anti-PTK7. FITC-labeled unselected Library (Lib-FITC) and PE-labeled IgG, which do not bind to CCRF-CEM cells, were used as control. Column 1 is the FITC channel, column 2 is the PE channel, and column 3 is the overlay of the two channels. Cells in row 1 were incubated with Lib-FITC (control) and IgG-PE (control). Cells in row 2 were incubated with Lib-FITC (control) and anti-PTK7-PE. Cells in row 3 were incubated with sgc8-FITC and anti-PTK7-PE.

    Article Snippet: CCRF-CEM (CCL-119, T-cell lines, human acute lymphoblastic leukemia), Ramos (CRL-1596, B-cell line, human Burkitt’s lymphoma), Jurkat (TIB-152, human acute T cell leukemia), Molt-4 (CRL-1582, T-cell lines, human acute lymphoblastic leukemia), Sup-T1(CRL-1942, T-cell lines, human lymphoblastic leukemia) and Toledo (CRL-2631, B-cell line, human diffuse large cell lymphoma) were all obtained from ATCC (American type Culture Collection); NB-4 (acute promyelocytic leukemia) were obtained from the Department of Pathology, University of Florida).

    Techniques: Fluorescence, Incubation, Labeling

    Antiproliferative activity of PhPP derivatives (50 µM) and doxorubicin (Dox) (1 µM) against CCRF-CEM ( A ), SK-OV-3 ( B ), HT-29 ( C ), and MDA-MB-231 ( D ) cell lines. All experiments were repeated in triplicate.

    Journal: Molecules

    Article Title: Phenylpyrazalopyrimidines as Tyrosine Kinase Inhibitors: Synthesis, Antiproliferative Activity, and Molecular Simulations

    doi: 10.3390/molecules25092135

    Figure Lengend Snippet: Antiproliferative activity of PhPP derivatives (50 µM) and doxorubicin (Dox) (1 µM) against CCRF-CEM ( A ), SK-OV-3 ( B ), HT-29 ( C ), and MDA-MB-231 ( D ) cell lines. All experiments were repeated in triplicate.

    Article Snippet: Cell Culture Human leukemia cell line CCRF-CEM (ATCC no. CCL-119), human ovarian adenocarcinoma cell line SK-OV-3 (ATCC no. HTB-77), human breast carcinoma cell line MDA-MB-231 (ATCC no.HTB-26), and human colon adenocarcinoma cell line HT-29 (ATCC no. HTB-38) were obtained from American Type Culture Collection.

    Techniques: Activity Assay, Multiple Displacement Amplification

    Histone O- GlcNAcylation is cell cycle-regulated as assessed by centrifugal elutriation. Asynchronously growing human acute T lymphoblastic leukemia cells, CCRF-CEM, were loaded into an elutriator rotor, and the flow rate was increased in steps to elute

    Journal: The Journal of Biological Chemistry

    Article Title: Modification of Histones by Sugar ?-N-Acetylglucosamine (GlcNAc) Occurs on Multiple Residues, Including Histone H3 Serine 10, and Is Cell Cycle-regulated *

    doi: 10.1074/jbc.M111.284885

    Figure Lengend Snippet: Histone O- GlcNAcylation is cell cycle-regulated as assessed by centrifugal elutriation. Asynchronously growing human acute T lymphoblastic leukemia cells, CCRF-CEM, were loaded into an elutriator rotor, and the flow rate was increased in steps to elute

    Article Snippet: Human CCRF- CEM, acute T lymphoblastic leukemia cell line, and K562, erythroleukemia cells (both from ATCC), were grown in RPMI 1640 medium (Lonza) supplemented with 10% FCS (Lonza) at 37 °C in a humidified atmosphere with 5% CO2 .

    Techniques: Flow Cytometry

    BCL and CD5 VLR-CAR constructs significantly increase the cytotoxic potential of effector cells when cultured with their target cells. ( a ) Representation of flow cytometry cytotoxicity assay using PKH26 and 7-AAD. Target cells were labeled with PKH26, while effector cells were unlabeled. Cell death was assessed using 7-AAD ( b ) Transduced, sorted, and expanded NK-92 cells were cocultured with CCRF-CEM cells. Significant increase in cytotoxicity ( P

    Journal: Molecular Therapy Oncolytics

    Article Title: Genetic engineering of chimeric antigen receptors using lamprey derived variable lymphocyte receptors

    doi: 10.1038/mto.2016.26

    Figure Lengend Snippet: BCL and CD5 VLR-CAR constructs significantly increase the cytotoxic potential of effector cells when cultured with their target cells. ( a ) Representation of flow cytometry cytotoxicity assay using PKH26 and 7-AAD. Target cells were labeled with PKH26, while effector cells were unlabeled. Cell death was assessed using 7-AAD ( b ) Transduced, sorted, and expanded NK-92 cells were cocultured with CCRF-CEM cells. Significant increase in cytotoxicity ( P

    Article Snippet: Cell lines Jurkat, BCL1-3B3 (BCL), and CCRF-CEM cell lines were obtained from American Type Culture Collection (ATCC, Manassas, VA).

    Techniques: Construct, Cell Culture, Flow Cytometry, Cytometry, Cytotoxicity Assay, Labeling